Agios Pharmaceuticals Shares Plunge After Halting Sickle Cell Drug Trial

Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) plunged 14% in trading on Tuesday after the company announced it was discontinuing the development of tebapivat, an experimental treatment for sickle cell disease. The decision followed a review of Phase 2 clinical trial data that failed to show a significant enough benefit to warrant further investment.

Trial Data Fails to Differentiate

Agios stated that the Phase 2 trial of tebapivat, an oral pyruvate kinase activator, did not demonstrate a sufficient level of differentiation to support its advancement. The 12-week study involved 59 patients with sickle cell disease and measured hemoglobin response as its primary endpoint.

While the company noted improvements in hemoglobin levels, the response rates did not clearly outperform the placebo group across all doses. Key results from the trial included:

• Placebo: 33.3% response rate
• 2.5 mg dose: 43.8% response rate
• 5.0 mg dose: 47.1% response rate
• 7.5 mg dose: 29.4% response rate

Ad

The company confirmed that the safety and tolerability profile of tebapivat was consistent with findings from previous trials.

Focus Shifts to Mitapivat

Following the discontinuation of tebapivat, Agios will increase its focus on its other pyruvate kinase activator, mitapivat, for the same indication. This drug represents the company's lead asset in its sickle cell disease pipeline.

Investors will be closely watching for developments with mitapivat, which is currently under Priority Review with the U.S. Food and Drug Administration (FDA). The agency accepted the company's supplemental New Drug Application for accelerated approval earlier this month and has set a Prescription Drug User Fee Act (PDUFA) goal date of November 1, 2026.